Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Fillip Findling

Surgery of the Hand Bronx, NY Doctor of Osteopathy

NPI 1326229196 CMS profile 242038

1650 Grand Concourse, Bronx Care Orthopaedics Gcon 7, Bronx, NY 10457

Open in the dashboard

General payments

$389

8 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Fillip Findling of Bronx, NY is reported in the CMS Open Payments database as having received $389 across 8 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 16th percentile of Surgery of the Hand profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47 2
2024 General $58 2
2022 General $17 1
2021 General $136 2
2019 General $130 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fillip Findling
  • Surgery of the Hand median
  • Middle half of Surgery of the Hand
  • National median

In program year 2025, general payments to Fillip Findling were reported at $47. Among 286 Surgery of the Hand profiles paid that year, the median was $288 and the middle half received between $115 and $1,242.

Show as a table
Year Fillip Findling Surgery of the Hand median Middle half National median
2019 $130 $369 $108–$1,516 $163
2020 $0 $153 $56–$898 $114
2021 $136 $261 $84–$1,296 $132
2022 $17 $313 $103–$1,562 $149
2023 $0 $241 $95–$876 $160
2024 $58 $236 $84–$890 $164
2025 $47 $288 $115–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Endo Pharmaceuticals Inc. $153 3 payments
  2. Stryker Corporation $130 1 payment
  3. PolyNovo North America LLC $36 1 payment
  4. Integra LifeSciences Corporation $30 1 payment
  5. Acumed LLC $22 1 payment
  6. Gotham Surgical Solutions & Devices, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $389 8 payments
Products named General payments · program years 2019–2025
  1. XIAFLEX $153 3 payments
  2. MAKO $130 1 payment
  3. NOVOSORB BTM $36 1 payment
  4. Integra Recon-Skin And Wound $30 1 payment
  5. Integra Recon-Skin And Wound $30 1 payment
  6. Integra Recon-Skin And Wound $30 1 payment
  7. INTEGRA DERMAL REGENERATION TEMPLATE $30 1 payment
  8. PRIMATRIX $30 1 payment
  9. INnate Implant $22 1 payment
  10. InFrame Implant $22 1 payment
  11. Other $22 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

478

Median for Hand Surgery: 118

Drug cost

$12,177

Median for Hand Surgery: $615

Branded share of claims

0%

Median for Hand Surgery: 34.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxepin Hcl Generic 59 $8,759
Meloxicam Generic 240 $1,734
Ibuprofen Generic 72 $701
Diclofenac Sodium Generic 31 $365
Cephalexin Generic 28 $342
Naproxen Generic 19 $116
Methylprednisolone Generic 11 $94
Oxycodone Hcl Generic 18 $67

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,399 Part D prescribers listed as Hand Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$43,544

Of which drugs: $165

Medicare patients

155

Average age 72

Services billed

728

96 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 73%
Diabetes 37%
Ischemic heart disease 28%
Cancer 21%
Chronic kidney disease 20%
Depression 15%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 43 206 $154

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

8 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery of the Hand in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record